Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 42Recruiting 12Terminated 10Active not recruiting 8Unknown 5Not yet recruiting 4Withdrawn 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 40Breast Neoplasms 40Prostatic Neoplasms 24Colorectal Neoplasms 24Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Lung Neoplasms 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 8Brain Neoplasms 8Urinary Bladder Neoplasms 7Sarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Ovarian Neoplasms 6Epilepsy 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Dementia 5Cholangiocarcinoma 5Recurrence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Neurofibrosarcoma × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡